Provision of information on regulatory authorities’ websites
Authors:
- A. VitryAVA. Vitry
- J. LexchinJLJ. Lexchin
- L. SasichLSL. Sasich
- T. Dupin-SprietTDT. Dupin-Spriet
- T. ReedTRT. Reed
- V. BerteleVBV. Bertele
- S. GarattiniSGS. Garattini
- L. ToopLTL. Toop
- E. HurleyEHE. Hurley
- 11 March 2008
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 38 (7) , 559-567
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005
- Transparency - in the eye of the beholder?Australian Prescriber, 2005
- Is This Clinical Trial Fully Registered? — A Statement from the International Committee of Medical Journal EditorsNew England Journal of Medicine, 2005
- EMEA: For Patients or For Industry?PharmacoEconomics, 2005
- Transparency in drug regulation: Mirage or oasis?Canadian Medical Association Journal, 2004
- NICE accuses drug companies of withholding dataBMJ, 2002
- Secrecy and transparency of medicines licensing in the EUThe Lancet, 1998